STAMFORD, Conn. and WHIPPANY, N.J., Nov. 26, 2018 (GLOBE NEWSWIRE) — The U.S. Food and Drug Administration (FDA) today approved Vitrakvi® (larotrectinib), the first ever oral TRK inhibitor, for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a …
Tag Archives: solid tumors
November, 2018
-
20 November
BioLineRx Announces Receipt of FDA Biological Product Designation for Novel Cancer Immunotherapy Candidate AGI-134
Tel Aviv, Israel, November 20, 2018 – BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that the U.S. Food and Drug Administration (FDA) has granted the Biological Product Designation for AGI-134, the Company’s novel immunotherapy compound. This designation provides the Company with eligibility …
-
15 November
Dragonfly and Celgene Expand Collaboration in Immunotherapies for Patients with Solid and Hematological Cancers
WALTHAM, Mass., Nov. 14, 2018 /PRNewswire/ — Dragonfly Therapeutics, Inc. (“Dragonfly” or the “Company”), today announced it entered into a new agreement with Celgene Corporation and its affiliates (“Celgene”) to discover, develop and commercialize innovative immunotherapies for patients with solid and hematological cancers. The new agreement builds upon Celgene’s existing …
-
9 November
Celldex Presents Promising Interim Data from Phase 1 Study of Differentiated CD40 Agonist CDX-1140
HAMPTON, N.J., Nov. 09, 2018 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented interim data today from the Phase 1 dose-escalation study of CDX-1140, a fully human agonist anti-CD40 antibody. CD40, expressed on dendritic cells and other antigen presenting cells, has long been an important target for immunotherapy, as it …
October, 2018
-
11 October
Bristol-Myers Squibb and Compugen Partner to Evaluate Therapeutic Regimen in Advanced Solid Tumors
NEW YORK & HOLON, Israel–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen’s COM701, an investigational anti-PVRIG antibody, in combination with Bristol-Myers Squibb’s programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab), in patients with advanced …
-
10 October
Genentech to Present New Positive Data from its Broad Cancer Immunotherapy Program and Across a Wide Range of Cancers
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new results from a number of studies across its industry-leading oncology portfolio of approved and investigational medicines will be presented at the European Society for Medical Oncology (ESMO) 2018 Congress, taking …
-
3 October
Kite and HiFiBiO Collaborate to Develop Technology for Potential Discovery of Neoantigen-Reactive T Cell Receptors for the Treatment of Cancer
SANTA MONICA, Calif. & HONG KONG–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), and HiFiBiO Therapeutics, a biotechnology company focused on the discovery of therapeutic antibodies through single B cell screening and analysis, announced the companies have entered into a research collaboration and license agreement to develop technology supporting the discovery …
-
3 October
Dragonfly Collaborates with Merck to Develop Novel Drug Candidates for Solid Tumors Using Dragonfly’s TriNKET Platform
WALTHAM, Mass., Oct. 1, 2018 /PRNewswire/ — Dragonfly Therapeutics, Inc. (“Dragonfly”), today announced a strategic collaboration with Merck, known as MSD outside the United States and Canada, through a subsidiary, to discover, develop and commercialize innovative immunotherapies for patients with solid tumor cancers. The collaboration grants Merck the option to …
July, 2018
-
25 July
Biocept and UC San Diego Moores Cancer Center Partner to Study Liquid Biopsy to Predict Disease Recurrence in Solid Tumors and Response to Therapy
SAN DIEGO, July 23, 2018 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will work with Moores Cancer Center at UC San Diego Health to conduct two clinical studies in patients with …
-
10 July
Boehringer Ingelheim Acquires Rights to MabVax’s Program Targeting a Glycan Overexpressed in Multiple Solid Tumors
SAN DIEGO, July 9, 2018 /PRNewswire/ — MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage oncology drug development company and Boehringer Ingelheim today announced they have signed an asset acquisition and related agreements centered on MabVax’s program targeting a glycan commonly overexpressed on multiple solid tumor cancers. Boehringer Ingelheim has …